24 assets in Clear Cell Renal Carcinoma

Therapeutic assets addressing Clear Cell Renal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Everolimus Clear Cell Renal Carcinoma	Peking University First Hospital	P2	BB (65)
Nivolumab Clear Cell Renal Carcinoma	Exelixis	P2	B (62)
Belzutifan Clear Cell Renal Carcinoma	José Claudio Casali da Rocha	P2	B (60)
Pembrolizumab Clear Cell Renal Carcinoma	Sairopa B.V.	P2	B (60)
Toripalimab Clear Cell Renal Carcinoma	RenJi Hospital	P2	B (60)
Zanzalintinib Clear Cell Renal Carcinoma	Kelly Fitzgerald, MD	P2	B (60)
[18F]F-RESCA-R8B4 Clear Cell Renal Carcinoma	RenJi Hospital	P2	CCC (53)
[18F]F-RESCA-RCCB6 Clear Cell Renal Carcinoma	RenJi Hospital	P2	CCC (53)
[18F]F-RESCA-RD06 Clear Cell Renal Carcinoma	RenJi Hospital	P2	CCC (53)
[68ga]ga-nota-r8b4 Clear Cell Renal Carcinoma	RenJi Hospital	P2	CCC (53)
[68ga]ga-nota-rd06 Clear Cell Renal Carcinoma	RenJi Hospital	P2	CCC (53)
Cardonilimab Clear Cell Renal Carcinoma	The First Hospital of Jilin University	P2	CCC (53)
Catequentinib Clear Cell Renal Carcinoma	Fudan University	P2	CCC (53)
Ivonescimab Clear Cell Renal Carcinoma	City of Hope Medical Center	P2	CCC (53)
Renvastinib Clear Cell Renal Carcinoma	The First Hospital of Jilin University	P2	CCC (53)
Tislelizumab Clear Cell Renal Carcinoma	Fudan University	P2	CCC (53)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Clear Cell Renal Carcinoma	Regeneron Pharmaceuticals	P1/2	CCC (48)
Regn10597 Clear Cell Renal Carcinoma	Regeneron Pharmaceuticals	P1/2	CCC (48)
Tinengotinib Clear Cell Renal Carcinoma	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	P1/2	CC (47)
Spartalizumab Clear Cell Renal Carcinoma	SOLTI Breast Cancer Research Group	P2	CC (46)
ab521 Clear Cell Renal Carcinoma	Exelixis	P1	CC (43)
Adu-1805 Clear Cell Renal Carcinoma	Sairopa B.V.	P1	CC (43)
Fruquintinib Clear Cell Renal Carcinoma	Peking University First Hospital	N/A	D (30)
hs-10516 Clear Cell Renal Carcinoma	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P1	NR ()